Novartis, Bristol Myers Squibb pause CAR-T trials for lupus and other autoimmune diseases for safety reviews

Novartis and Bristol Myers Squibb have paused their CAR-T trials for lupus and other autoimmune diseases to review safety concerns. CAR-T remains experimental, and continued research is needed to understand its benefits and risks.

This post was originally published on this site